{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:48:22Z","timestamp":1792144102403,"version":"4.4.0"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    T\u2010cell\/histiocyte\u2010rich large B\u2010cell lymphoma (THRLBCL) is a rare subtype of B\u2010cell non\u2010Hodgkin lymphoma with an aggressive clinical course and poor prognosis in the case of relapsed or refractory (\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    ) disease. Recently, anti\u2010CD19 chimeric antigen\u2010receptor (CAR) T\u2010cell therapy has been approved for the treatment of large B\u2010cell lymphoma (LBCL), but subgroup\u2010specific outcomes in these patients have never been reported. Therefore, only limited retrospective data on the safety and efficacy of CAR T\u2010cell therapy in\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    THRLBCL is available. To comprehensively evaluate outcomes of CAR T\u2010cell recipients with\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    THRLBCL, we performed a systematic literature review (SLR) and meta\u2010analysis (MA). The SLR identified seven studies including 157 patients with\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    THRLBCL. Pooled overall response rates and complete remission rates were 48.3% and 30.4%, respectively. Median progression\u2010free survival was 3.4\u2009months, with a 12\u2010month rate of 29.1% and median overall survival was 15.0\u2009months, with a 12\u2010month rate of 57.4%. Low\u2010 and high\u2010grade cytokine release syndrome occurred in 68.3% and 4.5% of patients while low\u2010 and high\u2010grade immune effector cell\u2010associated neurotoxicity syndrome was seen in 23.1% and 12.9% of the patients. Overall, no unexpected safety signals were identified in\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    THRLBCL patients receiving CAR T\u2010cell therapy but durable responses were only achieved in a subset of patients.\n                  <\/jats:p>","DOI":"10.1111\/ejh.70340","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:20:11Z","timestamp":1792142411000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T\u2010Cell Therapy in T Cell\/Histiocyte\u2010Rich Large B\u2010Cell Lymphoma: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6345-4675","authenticated-orcid":false,"given":"Stefan","family":"Koeck","sequence":"first","affiliation":[{"name":"Department of Internal Medicine V Medical University of Innsbruck  Innsbruck Tyrol Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Cancer Research Laboratory of the Department of Internal Medicine III Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-1462","authenticated-orcid":false,"given":"Bernd","family":"Sch\u00f6pf","sequence":"additional","affiliation":[{"name":"Gilead iiSciences GesmbH  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-7464","authenticated-orcid":false,"given":"Josia","family":"Fauser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V Medical University of Innsbruck  Innsbruck Tyrol Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V Medical University of Innsbruck  Innsbruck Tyrol Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-8099","authenticated-orcid":false,"given":"Nina","family":"Worel","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1009-7710","authenticated-orcid":false,"given":"Gianfranco","family":"Pocobelli","sequence":"additional","affiliation":[{"name":"Clinical Research Center Salzburg GmbH, Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-3631","authenticated-orcid":false,"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Cancer Research Laboratory of the Department of Internal Medicine III Paracelsus Medical University  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"20","key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow S. H.","year":"2016","journal-title":"Blood"},{"issue":"9","key":"e_1_2_9_3_1","first-page":"3005","article-title":"T\u2010Cell\/Histiocyte\u2010Rich Large B\u2010Cell Lymphoma and Nodular Lymphocyte\u2010Predominant Hodgkin Lymphoma: A Spectrum of Disease","volume":"106","author":"Traverse\u2010Glehen A.","year":"2005","journal-title":"Blood"},{"issue":"1","key":"e_1_2_9_4_1","first-page":"6","article-title":"Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence","volume":"185","author":"Ollila T. A.","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"1","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long\u2010Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B\u2010Cell Lymphoma (ZUMA\u20101)","volume":"20","author":"Locke F. L.","year":"2019","journal-title":"Lancet Oncology"},{"issue":"1","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma","volume":"380","author":"Schuster S. J.","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"10254","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B\u2010Cell Lymphomas (TRANSCEND NHL 001)","volume":"396","author":"Abramson J. S.","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"e_1_2_9_8_1","first-page":"3119","article-title":"Experience With Axicabtagene Ciloleucel in Large B\u2010Cell Lymphoma: Real\u2010World Outcomes","volume":"38","author":"Bennani N. N.","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"e_1_2_9_9_1","first-page":"3090","article-title":"Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non\u2010Hodgkin Lymphoma (Including Transformed Cases)","volume":"40","author":"Jacobson C. A.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"e_1_2_9_10_1","first-page":"e93","article-title":"T\u2010Cell\/Histiocyte\u2010Rich Large B\u2010Cell Lymphoma: Clinical Presentation, Biology, and Therapeutic Challenges","volume":"102","author":"Sarkozy C.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_9_11_1","first-page":"54","article-title":"Mechanisms of Immune Evasion and Immune Modulation in Lymphoma","volume":"11","author":"Menter T.","year":"2018","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006464"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009148"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013863"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010078384"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/publications14010004"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001308\u20108"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.289196","article-title":"Anti\u2010CD19 CAR T\u2010Cell Therapy in Relapsed\/Refractory T\u2010Cell\/Histiocyte\u2010Rich Large B\u2010Cell Lymphoma: Insights From the French DESCAR\u2010T Registry, a LYSA Study","author":"Andr\u00e9 A.","year":"2026","journal-title":"Haematologica"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70077"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70096_662"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010182204"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010211784"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20107246"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.017"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.834113"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2026.100032"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017120"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19883"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199265"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007779"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201025\u20100602"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010016"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010026\u201002993\u20104"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.03.011"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70340","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:20:14Z","timestamp":1792142414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":34,"alternative-id":["10.1111\/ejh.70340"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70340","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70340"}}